Expansion of clinical trial enrollment criteria: what would we gain?
Expansion of clinical trial enrollment criteria:
Small-cell tumors: improvements in the second-line setting
Small-cell tumors: improvements in the second-li
Rare mutations: taking treatment one step further
Rare mutations: taking treatment one step furthe
Interview: Blood-based testing in ALK-positive disease
Blood-based testing in ALK-positive disease Int
Trial updates and new biomarkers in the field of immunotherapy
Trial updates and new biomarkers in the field of
Novel first-line options and other insights in EGFR-mutant lung cancer
Novel first-line options and other insights in E
Early-stage NSCLC: promising (neo)adjuvant approaches
Early-stage NSCLC: promising (neo)adjuvant appro
Preface – ASCO 2019
Preface – ASCO 2019 Elisabeth Quoix, MD Dep
